List of Excipients in Branded Drug WELLBUTRIN SR

Generic Drugs Containing WELLBUTRIN SR

Company	Ingredient	NDC	Excipient
DIRECT RX	bupropion hcl er (sr)	61919-036	ANHYDROUS LACTOSE
DIRECT RX	bupropion hcl er (sr)	61919-036	HYDROXYPROPYL CELLULOSE
DIRECT RX	bupropion hcl er (sr)	61919-036	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in WELLBUTRIN SR?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	HYDROXYPROPYL CELLULOSE
1	POLYETHYLENE GLYCOL 3350

Wellbutrin SR Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Wellbutrin SR is a twice-daily sustained-release tablet containing bupropion hydrochloride in 100 mg, 150 mg, and 200 mg strengths. Its commercial value is no longer protected primarily by brand exclusivity. The main opportunities are generic supply, excipient substitution, manufacturing efficiency, differentiated modified-release products, and lifecycle products that improve adherence without materially changing bupropion exposure.

The technical constraint is significant: bupropion has a dose-related seizure risk, and excessive peak concentrations can increase safety concerns. Any excipient or process change must preserve the approved sustained-release profile, tablet robustness, dose uniformity, and bioequivalence profile. The strongest commercial strategy is therefore a controlled-release matrix platform with low formulation complexity, reliable scale-up, and robust in vitro-in vivo performance.

What is Wellbutrin SR and how is it formulated?

Wellbutrin SR is an FDA-approved sustained-release oral tablet containing bupropion hydrochloride. It is approved for major depressive disorder and is administered in divided doses, generally with at least eight hours between doses. The product is also associated with the bupropion brand family that includes Wellbutrin XL and Zyban, although those products have different dosage forms, release profiles, and approved uses. [1]

Wellbutrin SR dosage strengths and dosage form

Product	Active ingredient	Strengths	Release type	Typical administration
Wellbutrin SR	Bupropion hydrochloride	100 mg, 150 mg, 200 mg	Sustained release	Twice daily
Wellbutrin XL	Bupropion hydrochloride	150 mg, 300 mg	Extended release	Once daily
Zyban	Bupropion hydrochloride	150 mg	Sustained release	Smoking cessation regimen

Wellbutrin SR tablets must be swallowed whole. They should not be crushed, split, or chewed because mechanical disruption can alter release and increase the rate of bupropion delivery. [1]

Which excipients are used in Wellbutrin SR?

Public labeling identifies a controlled-release tablet architecture that uses hydrophilic polymers, fillers, binders, lubricants, coating materials, and colorants. Depending on strength and market presentation, labeled inactive ingredients include materials such as hypromellose, hydroxypropyl cellulose, microcrystalline cellulose, povidone, polyethylene glycol, silicon dioxide, magnesium stearate, titanium dioxide, and approved colorants. Exact excipient composition and quantity can vary by strength and manufacturing site. [1]

Excipient class	Likely function in the product	Commercial significance
Hypromellose	Hydrophilic release-control polymer	Controls water penetration and drug diffusion
Hydroxypropyl cellulose	Binder and matrix modifier	Supports granulation and matrix integrity
Microcrystalline cellulose	Diluent and compression aid	Improves tablet hardness and manufacturability
Povidone	Binder and processing aid	Supports granule formation and content uniformity
Silicon dioxide	Glidant	Improves powder flow
Magnesium stearate or equivalent lubricant	Reduces tooling friction	Excess use can slow dissolution and weaken tablets
Polyethylene glycol	Coating or film-forming component	Supports coating performance
Titanium dioxide and colorants	Appearance and product identification	Reduce medication-error risk between strengths

The key formulation feature is the release-controlling polymer system. The commercial objective is not simply to reproduce the tablet’s excipient list. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence, while a new formulation developer may use a different excipient system if it achieves the required performance and regulatory pathway.

What excipient strategy best supports a Wellbutrin SR generic?

The most defensible strategy is a hydrophilic matrix tablet with a narrow dissolution target and a manufacturing process that limits variability in polymer distribution, granule density, tablet hardness, and lubricant exposure.

Hydrophilic matrix strategy

A hydrophilic matrix based on hypromellose or a comparable cellulose ether can provide sustained release through hydration, gel formation, diffusion, and gradual matrix erosion. The main variables are:

• Polymer viscosity grade
• Polymer loading
• Particle-size distribution
• Drug-to-polymer ratio
• Granulation method
• Compression force
• Tablet porosity
• Lubrication time and concentration
• Coating weight gain

Higher polymer loading generally slows drug release, but excessive polymer can produce a release curve that is difficult to match to the reference product. Lower polymer loading can create an initial release surge or unacceptable batch-to-batch variability.

A robust development program should establish a design space linking polymer grade, tablet hardness, porosity, and dissolution. Dissolution should be assessed across multiple media and agitation conditions rather than through a single release test.

Direct compression versus wet granulation

Direct compression can lower manufacturing cost and reduce processing steps. It requires consistent powder flow, compressibility, and segregation control. Bupropion hydrochloride loading, particle-size distribution, and excipient density can create challenges for content uniformity in a direct-compression platform.

Wet granulation may improve blend uniformity and tablet robustness, but it adds water exposure, drying controls, energy consumption, and process time. The preferred method depends on the drug substance and excipient physical properties, not only on nominal cost.

Manufacturing approach	Advantages	Risks
Direct compression	Fewer steps, lower capital burden, shorter cycle time	Segregation, poor flow, variable compression behavior
Dry granulation	No water exposure, scalable, suitable for moisture-sensitive systems	Ribbon-density variability, fines generation, dissolution shifts
Wet granulation	Strong content uniformity and tablet strength	Drying variability, longer cycle time, possible polymer distribution changes

For a bupropion sustained-release product, dry granulation or carefully controlled wet granulation may offer a better balance than an unconstrained direct-compression process. The commercial choice should be based on process capability and dissolution reproducibility.

What formulation patents protect Wellbutrin SR?

The original commercial protection for sustained-release bupropion was directed to the drug product and release technology rather than to an irreplaceable excipient alone. The relevant composition-of-matter protection for bupropion is expired, and the principal commercial opportunity is generic or reformulated competition rather than new-product exclusivity.

Current FDA Orange Book review is the controlling source for any live, listed patents and regulatory exclusivity associated with a specific reference product. [2] Historical patent protection for sustained-release bupropion does not create a meaningful barrier to a conventional ANDA where listed patents and exclusivity have expired or been addressed through the applicable certification pathway.

Are there active Orange Book patents for Wellbutrin SR?

Wellbutrin SR is an established small-molecule product with long-standing generic competition. It does not have biosimilar exclusivity, and its commercial position is not comparable to a recently approved branded product with active composition-of-matter protection.

A current Orange Book assessment should distinguish among:

1. The discontinued or unmarketed brand presentation.
2. The reference listed drug used for ANDA comparison.
3. Any listed method-of-use or formulation patents.
4. Patent certifications filed by individual ANDA applicants.
5. FDA approval status for each generic strength.

Patent risk can differ by strength, label, manufacturer, and reference product. The principal commercial risk is generally competition and price erosion, not a novel blocking patent.

When does Wellbutrin SR lose exclusivity?

Wellbutrin SR lost practical market exclusivity years ago. Generic bupropion sustained-release tablets are available, and the product is subject to established ANDA competition. FDA approval of a generic depends on pharmaceutical equivalence, bioequivalence, manufacturing controls, labeling, and resolution of applicable patent certifications. [2,3]

What was the impact of Paragraph IV challenges?

Paragraph IV litigation historically affected bupropion products, particularly where generic applicants challenged patents covering sustained-release or extended-release formulations. The most important distinction is between:

• Wellbutrin SR, a twice-daily sustained-release tablet.
• Wellbutrin XL, a once-daily extended-release tablet.
• Zyban, a smoking-cessation product using bupropion sustained release.

Patent disputes involving Wellbutrin XL or Zyban should not automatically be treated as disputes covering Wellbutrin SR. The dosage form, release mechanism, labeling, and listed patents can differ materially.

No single historical litigation event creates a current market-wide barrier for generic Wellbutrin SR. The relevant issue for a new entrant is whether a proposed product can obtain approval without infringing any live listed patent or whether a certification, litigation strategy, or settlement is required.

What excipients create the largest technical and regulatory risks?

Release-rate variability

The most important risk is an altered dissolution profile. A change in polymer viscosity, particle size, supplier, moisture level, or compression force can shift the time course of bupropion release. The product must avoid an unintended immediate-release component or excessive early exposure.

Dose dumping

Alcohol, mechanical disruption, or food effects can alter modified-release performance. Although the approved label does not authorize crushing or chewing, a robust formulation should be evaluated for sensitivity to physical abuse and common use errors. Any major dose-dumping signal would create a significant regulatory and commercial problem.

Lubricant sensitivity

Magnesium stearate and similar lubricants can form hydrophobic films around particles when overused or overmixed. That may slow dissolution, weaken interparticle bonding, or increase tablet-failure rates. Lubricant concentration and blending time should be treated as critical process variables.

Polymer supplier changes

A polymer change can be more consequential than a nominally minor excipient substitution. Viscosity, substitution pattern, particle size, moisture content, and lot-to-lot behavior can alter release. Supplier qualification should include comparative dissolution and tablet mechanical testing.

Colorant and coating changes

Colorants and film coats usually have a limited effect on drug release when applied at low weight gain, but they affect appearance, strength identification, stability, and patient acceptability. A change in color can create medication-error concerns if the strength presentation becomes visually similar to another tablet.

What commercial opportunities exist for Wellbutrin SR excipients?

Generic bupropion SR supply

The largest opportunity is reliable, low-cost generic supply. A manufacturer that combines a stable matrix formulation with high process capability can compete through:

• Lower tablet manufacturing cost
• Reduced batch failure rates
• Dual-source excipient procurement
• Improved yield
• Higher packaging-line throughput
• Fewer dissolution-related investigations

Because the active ingredient is established and generic competition is mature, operational execution matters more than novel excipient claims.

Excipient substitution and supply-chain resilience

Potential opportunities include replacing an incumbent excipient with:

• A lower-cost equivalent-grade polymer
• A directly compressible cellulose system
• A co-processed filler-binder
• A lower-dusting glidant
• A lubricant with less dissolution impact
• A coating system that reduces solvent, energy, or processing time

The substitution must preserve critical quality attributes. A formulation that reduces cost but produces variable dissolution is commercially weak.

Once-daily lifecycle products

The strongest patient-oriented opportunity is a once-daily product, but that is primarily a release-design and regulatory opportunity rather than a simple excipient substitution. Wellbutrin XL already occupies this segment. A new product would need a clear clinical, adherence, tolerability, or manufacturing advantage over existing bupropion XL products.

Possible differentiation includes:

• More consistent plasma exposure
• Lower peak-to-trough fluctuation
• Improved tolerability
• Reduced pill burden
• Simplified titration
• Better robustness against food or alcohol effects

A materially different release profile may require a 505(b)(2) application rather than a conventional ANDA. [3]

Patient-friendly dosage forms

Potential products include smaller tablets, alternative strengths, or modified administration formats. However, bupropion’s safety profile limits the attractiveness of chewable, crushable, orally disintegrating, or sprinkle formulations. A dosage form that enables rapid drug release could create avoidable seizure-risk concerns.

Contract development and manufacturing

CDMOs can create value through validated sustained-release platforms, scale-up expertise, and comparative dissolution modeling. The platform may be transferable to other low-dose or moderate-dose modified-release molecules, although bupropion-specific bioequivalence data would remain product-specific.

How does Wellbutrin SR compare with Wellbutrin XL and generic bupropion?

Attribute	Wellbutrin SR	Wellbutrin XL	Generic bupropion SR
Dosing	Twice daily	Once daily	Twice daily
Release profile	Sustained release	Extended release	Must match applicable reference product
Main commercial position	Established brand and generic	Brand and generic once-daily segment	Price-driven generic market
Excipient priority	Matrix release control	Longer-duration release and dose uniformity	Bioequivalence and cost control
Main technical risk	Early release and dose dumping	Failure to reproduce long release duration	Batch variability and price erosion
Biosimilar exposure	None	None	None

Wellbutrin XL has stronger adherence positioning because of once-daily administration, while Wellbutrin SR may remain attractive where prescribers or patients prefer divided dosing, where generic pricing is decisive, or where a particular titration strategy is used.

What is the FDA regulatory status of Wellbutrin SR?

Wellbutrin SR is an FDA-approved small-molecule prescription product. It is not a biologic and does not have biosimilar competition. Generic versions are approved through the ANDA pathway when they meet the relevant standards for pharmaceutical equivalence and bioequivalence. [1,3]

A new excipient formulation may remain eligible for an ANDA if it is therapeutically equivalent to the reference product and does not require new clinical efficacy evidence. A different dosing regimen, new indication, materially different release profile, or clinical advantage may move the product toward a 505(b)(2) pathway.

What generic entry risks exist for Wellbutrin SR?

The principal risks are commercial:

1. Multiple approved manufacturers can compress prices.
2. Retail substitution can reduce brand share.
3. Wholesaler and pharmacy contracting can favor large-volume suppliers.
4. Temporary shortages can create opportunities for alternate suppliers but may not produce durable share.
5. Excipient or API supply disruptions can cause manufacturing interruptions.
6. A technically non-equivalent release profile can lead to FDA deficiencies, recalls, or loss of customer confidence.

A new entrant should prioritize consistent supply and low failure rates over a highly differentiated excipient claim. In a mature generic market, quality metrics and cost per saleable tablet are usually more important than incremental formulation novelty.

How strong is the Wellbutrin SR patent estate?

The patent estate is commercially weak as a barrier to conventional generic entry because the product has faced generic competition for many years and its core small-molecule exclusivity has expired. Residual risk may arise from product-specific listed patents, labeling limitations, manufacturing know-how, or pending regulatory actions, but these are narrower than an active composition-of-matter patent.

The strongest defensible intellectual property for a new entrant would likely involve:

• A specific excipient ratio linked to a defined release profile
• A manufacturing process that improves dissolution uniformity
• A particle-engineering method
• A stable formulation with reduced impurity formation
• A novel once-daily or abuse-resistant delivery system
• A clinically meaningful performance advantage

A broad claim covering “bupropion plus a sustained-release polymer” would face substantial validity and freedom-to-operate challenges because sustained-release bupropion technology is longstanding.

Key Takeaways

• Wellbutrin SR is a twice-daily sustained-release bupropion hydrochloride tablet in 100 mg, 150 mg, and 200 mg strengths.
• The core excipient strategy relies on a hydrophilic matrix, compression aids, binders, lubricants, and a protective coating.
• The primary technical challenge is preserving the reference product’s release profile and avoiding dose dumping.
• The practical commercial opportunity is generic manufacturing, excipient substitution, supply-chain resilience, and process-cost reduction.
• Wellbutrin SR has no biosimilar pathway because bupropion is a small molecule.
• Wellbutrin XL is the principal branded comparator for once-daily adherence and extended-release differentiation.
• A materially different release profile may require a 505(b)(2) application rather than an ANDA.
• The historical patent estate is not a significant market-wide barrier, although product-specific Orange Book and litigation review remains relevant.
• A low-variability, low-cost matrix formulation is more commercially attractive than an excipient system built around marginal novelty.

FAQs About Wellbutrin SR Excipient and Commercial Strategy

Can hypromellose be replaced in a generic Wellbutrin SR formulation?

Yes. A generic developer may use a different release-controlling polymer or polymer grade if the finished product meets applicable pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

Is Wellbutrin SR suitable for an abuse-deterrent formulation?

It is technically possible to develop an abuse-resistant dosage form, but the safety rationale must be strong. Increasing resistance to crushing or extraction cannot compromise the approved release profile or create higher exposure under foreseeable misuse conditions.

Does Wellbutrin SR require a biologic or biosimilar development pathway?

No. Bupropion hydrochloride is a chemically synthesized small molecule. Generic products generally proceed through the ANDA pathway, subject to FDA requirements.

Can a manufacturer obtain new exclusivity through a novel Wellbutrin SR excipient combination?

A novel excipient combination may support patent protection, but it does not automatically create regulatory exclusivity. The product would need a qualifying regulatory basis and a patentable, non-obvious technical contribution.

Which is the stronger commercial opportunity, Wellbutrin SR or Wellbutrin XL?

Wellbutrin SR is generally the lower-cost, mature generic opportunity. Wellbutrin XL offers more room for adherence, pharmacokinetic, and once-daily formulation differentiation, but it also requires tighter control of the extended-release profile and faces established generic competition.

References

1. U.S. Food and Drug Administration. (2024). Wellbutrin SR (bupropion hydrochloride) sustained-release tablets: Prescribing information. GlaxoSmithKline LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format of an abbreviated new drug application. FDA Guidance for Industry.

4. U.S. Food and Drug Administration. (2023). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. FDA Guidance for Industry.